August 10, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. (ADMA Biologics) (NASDAQ: ADMA) on behalf of those who purchased or acquired ADMA Biologics securities between August 9, 2024 and March 25, 2026, inclusive. The lawsuit is filed in the United States District Court for the District of New Jersey and is captioned Mazzarino v. ADMA Biologics, Inc., Case No. 2:26-cv-06918 (D.N.J.). Investors have until August 10, 2026, to file for lead plaintiff status.

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired ADMA Biologics securities and have lost money on your investment, please provide your information here:

https://www.ktmc.com/adma-adma-biologics-inc-class-action-lawsuit?utm_ ...

You can also contact attorney Jonathan Naji, Esq. by calling [phone] or by email at [e-mail]. There is no cost or obligation to speak with an attorney.

ADMA BIOLOGICS, INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, Defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Why did AMDA Biologics’ s Stock Drop?
On March 24, 2026, Culper Research published a report concerning ADMA Biologics alleging “Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” Among other things, the report stated that “two high-level employees at one of ADMA's two largest distributors” had confirmed independently that, “starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations”, and that “Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there.”

Schreibe Deinen Kommentar